药物发现资讯学市场机会、成长动力、产业趋势分析与预测 2025 - 2034

2024 年全球药物发现资讯学市场价值为 35 亿美元，预计 2025 年至 2034 年期间的复合年增长率将达到惊人的 11.5%。

慢性病发病率的上升和对精准医疗的日益重视，推动了创新资讯工具的采用，以简化药物发现流程、提高效率并促进突破性治疗。在基因和分子分析技术进步的推动下，个人化治疗方法的转变进一步增加了对复杂资讯学解决方案的需求。这些技术在识别生物标记、实现患者分层和提高药物开发成果方面发挥关键作用。随着製药业继续优先考虑效率和创新，预计市场将保持强劲的成长轨迹。

研发方面的投资大大促进了旨在优化药物研发工作流程的资讯平台的采用。随着製药公司投入大量资源开发尖端疗法，资讯工具在管理目标识别、先导优化和临床资料整合等复杂流程中变得不可或缺。这些平台分析大型数据集、整合多组学资料和支持精准医疗计划的能力正在改变药物发现的模式。这些进步促进了针对特定患者的治疗方法的发展，满足了全球对个人化医疗解决方案日益增长的需求。

市场按产品类型细分为软体和服务，其中软体部分占主导地位，到 2024 年将达到 22 亿美元。它们在支持精准医疗方面发挥关键作用，精准医疗需要详细的基因组学、蛋白质组学和临床资料分析，这凸显了它们日益增长的重要性。这些工具使研究人员能够发现针对患者的具体见解并加速创新疗法的开发，从而进一步推动市场成长。

依照功能，市场包括定序和目标资料分析、对接、分子建模等。 2024年，定序和目标资料分析占据了42.5%的市场份额，突显了其对基因组学和表观基因组学研究的变革性影响。下一代定序 (NGS) 和高通量技术彻底改变了基因变异的识别，为新型药物标靶提供了关键见解。这些进步提高了药物开发的效率，为更精准、更有效的治疗铺平了道路。

美国仍然是药物发现资讯学市场的主导者，到 2024 年其市场规模将达到 14 亿美元。政府措施和强劲的私人资金正在推动个人化医疗、基因组学和生物製剂的进步。根据个人基因特征制定治疗方案的重点继续推动对先进资讯学工具的需求，巩固了美国作为药物研发进步中心的地位。

目录

第 1 章：方法论与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 个人化医疗需求日益增长
    • 药物研发方面的研发投入不断增加
    • 慢性病盛行率不断上升
    • 云端运算和人工智慧的技术进步
  • 产业陷阱与挑战
    • 资讯学工具和实施成本高昂
    • 资料整合和管理的复杂性
• 成长潜力分析
• 监管格局
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第 5 章：市场估计与预测：按产品类型，2021 年至 2034 年

• 主要趋势
• 软体
• 服务

第六章：市场估计与预测：按功能，2021 – 2034 年

• 主要趋势
• 定序和目标资料分析
• 对接
• 分子建模
• 其他功能

第 7 章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 药物研发
• 药物开发

第 8 章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 製药和生物技术公司
• 合约研究组织 (CRO)
• 学术和研究机构
• 其他最终用户

第 9 章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Accenture
• Agilent Technologies
• Albany Molecular Research
• Boehringer Ingelheim International
• Charles River Laboratories
• Collaborative Drug Discovery
• Eurofins Scientific
• Illumina
• Jubilant Life Sciences
• Novo Informatics
• Oracle Corporation
• Selvita

The Global Drug Discovery Informatics Market, valued at USD 3.5 billion in 2024, is projected to grow at an impressive CAGR of 11.5% between 2025 and 2034. This rapid expansion is fueled by escalating investments in research and development across pharmaceutical and biotechnology sectors, with a particular focus on advancing treatments in oncology, infectious diseases, and personalized medicine.

The rising prevalence of chronic conditions and the increasing emphasis on precision medicine are driving the adoption of innovative informatics tools that streamline drug discovery processes, improve efficiency, and facilitate groundbreaking therapies. The shift toward personalized treatment approaches, underpinned by advancements in genetic and molecular profiling, is further amplifying the demand for sophisticated informatics solutions. These technologies play a pivotal role in identifying biomarkers, enabling patient stratification, and enhancing outcomes in drug development. As the pharmaceutical industry continues to prioritize efficiency and innovation, the market is expected to maintain a robust growth trajectory.

Investments in R&D have significantly boosted the adoption of informatics platforms designed to optimize workflows in drug discovery. With pharmaceutical companies channeling substantial resources into developing cutting-edge therapies, informatics tools are becoming indispensable in managing complex processes such as target identification, lead optimization, and clinical data integration. The ability of these platforms to analyze large datasets, integrate multi-omics data, and support precision medicine initiatives is transforming the drug discovery landscape. These advancements enable the development of patient-specific treatments, addressing the growing global demand for personalized healthcare solutions.

The market is segmented by product type into software and services, with the software segment dominating at USD 2.2 billion in 2024. Software solutions are integral to modern drug discovery, managing intricate processes, and analyzing extensive datasets. Their critical role in supporting precision medicine, which requires detailed genomic, proteomic, and clinical data analysis, underscores their growing importance. These tools empower researchers to uncover patient-specific insights and accelerate the development of innovative therapies, further driving market growth.

By functionality, the market includes sequencing and target data analysis, docking, molecular modeling, and others. In 2024, sequencing and target data analysis captured 42.5% of the market share, highlighting its transformative impact on genomic and epigenomic research. Next-generation sequencing (NGS) and high-throughput technologies have revolutionized the identification of genetic variations, offering critical insights into novel drug targets. These advancements are enhancing the efficiency of drug development and paving the way for more precise and effective treatments.

The United States remains a dominant player in the drug discovery informatics market, achieving USD 1.4 billion in 2024. The country's leadership stems from its high prevalence of chronic diseases and extensive investments in drug discovery innovation. Government initiatives and robust private funding are propelling advancements in personalized medicine, genomics, and biologics. The focus on tailoring treatments to individual genetic profiles continues to drive demand for advanced informatics tools, solidifying the US as a hub for drug discovery advancements.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for personalized medicine
    • 3.2.1.2 Rising research and development investments in drug discovery
    • 3.2.1.3 Growing prevalence of chronic disease
    • 3.2.1.4 Technological advancement in cloud computing and AI
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of informatics tools and implementation
    • 3.2.2.2 Complexity of data integration and management
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter’s analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Software
• 5.3 Services

Chapter 6 Market Estimates and Forecast, By Functionality, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Sequencing and target data analysis
• 6.3 Docking
• 6.4 Molecular modeling
• 6.5 Other functionalities

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Drug discovery
• 7.3 Drug development

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceutical and biotechnology companies
• 8.3 Contract research organizations (CROs)
• 8.4 Academic and research institutes
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Accenture
• 10.2 Agilent Technologies
• 10.3 Albany Molecular Research
• 10.4 Boehringer Ingelheim International
• 10.5 Charles River Laboratories
• 10.6 Collaborative Drug Discovery
• 10.7 Eurofins Scientific
• 10.8 Illumina
• 10.9 Jubilant Life Sciences
• 10.10 Novo Informatics
• 10.11 Oracle Corporation
• 10.12 Selvita